Skip to content
Peptigraph home

Cagrilintide Half-Life: How Long It Stays in Your System

How long Cagrilintide stays in the body, how that shapes dosing frequency, and what is known about drug testing.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureAmylin analogUpdated
Half-life
159-195 h (with semaglutide 2.4 mg co-administered)
subcutaneous, in people · Lancet 2021, PMID 33894838
Dosing interval
Varies by study
as used in studies
WADA
Prohibited (S0)
In and out of competition
Detection window
Not found
None reported as of 2 Oct 2026

Cagrilintide half-life

A half-life depends on the route (under the skin, into a vein, by mouth or nasal spray) and the species it was measured in, so we report each value with its route and source.

Cagrilintide half-life by route
RouteHalf-lifeMeasured inSource
subcutaneous159-195 h (with semaglutide 2.4 mg co-administered)PeopleLancet 2021, PMID 33894838

What half-life means

Half-life is the time it takes for the amount of a drug in the blood to fall by half. After one half-life, about 50% is left; after two, about 25%; after four to five, only a few percent remain.

  • A long half-life lets a drug be dosed less often, for example once a week.
  • A short half-life means levels rise and fall quickly, which is why some peptides are given daily or more often.
  • Effects can outlast blood levels, so half-life alone does not tell you how long a drug works.

What it means for dosing frequency

Dosing intervals used in published studies of Cagrilintide:

Changing the interval changes how much drug builds up between doses, so it is not a free choice.

Drug tests and sport

Prohibited by WADA (S0)

Cagrilintide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change.

Anti-doping labs use tests built for specific substances. Whether a given test detects Cagrilintide, and for how long, is not reported in the anti-doping literature we checked (as of 2 Oct 2026). Tested athletes should treat it as prohibited (s0) at all times.

The phase 1b figure

In a trial of multiple cagrilintide doses given alongside semaglutide, cagrilintide had a half-life of 159-195 h with a median tmax of 24-72 h.[2]

159 h is 6.6 days and 195 h is 8.1 days, so five half-lives span about 33 to 41 days.

Calculated from low h 159; high h 195; low days 159 / 24 = 6.6; high days 195 / 24 = 8.1; five half lives days 5 x 6.6 = 33.1; 5 x 8.1 = 40.6; remaining after 5 3.1%. Formula: days = hours / 24; washout = 5 x half-life

Kidney and liver impairment

Two single-dose studies found cagrilintide exposure similar across groups with normal, mild, moderate or severe renal or hepatic impairment.[3]

Approval and doping status

Drugs@FDA returns no cagrilintide product on its own, so there is no label.[7]

WADA does not name cagrilintide. Its S0 clause covers substances with no current approval for human therapeutic use, and no cagrilintide product appears in Drugs@FDA.[1]

Common questions

How long does Cagrilintide stay in your system?

Its reported half-life is 159-195 h (with semaglutide 2.4 mg co-administered) (subcutaneous). Most of a dose is gone after about four to five half-lives.

What is the half-life of cagrilintide?

159-195 h in a phase 1b trial when given with semaglutide.[2]

Is Cagrilintide on the WADA prohibited list?

Yes. Prohibited by WADA (S0).

Does kidney or liver disease change cagrilintide levels?

In single-dose studies the exposure was similar across impairment groups.[3]

More on Cagrilintide

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.Lancet (London, England) · 2021PMID 33894838Accessed 2 Oct 2026
  3. 3Renal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.Clinical pharmacokinetics · 2026PMID 42228334Accessed 2 Oct 2026
  4. 4Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants.Diabetes, obesity & metabolism · 2024PMID 39279639Accessed 2 Oct 2026
  5. 5Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.Lancet (London, England) · 2021PMID 34798060Accessed 2 Oct 2026
  6. 6Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.Lancet (London, England) · 2023PMID 37364590Accessed 11 Oct 2026
  7. 7Drugs@FDA (openFDA) search: active ingredient "cagrilintide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.